Medical treatment of glaucoma: Present and future

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 947-959

  Fogagnolo, Paolo ^a   Rossetti, Luca ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

blockers; actin cytoskeleton; benzalconyum chloride; extracellular matrix; gene therapy; glaucoma; intraocular pressure; MMPs; ocular implants; prostaglandin analogs; rho kinase (ROCK1; ROCK2) inhibitors; trabecular meshwork

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AR 12286; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE PLUS TIMOLOL; CALCIUM ANTAGONIST; CARBONATE DEHYDRATASE INHIBITOR; CATIOPROST; DILTIAZEM; DORZOLAMIDE PLUS TIMOLOL; FLUNARIZINE; INO 8875; LATANOPROST; LATANOPROST PLUS TIMOLOL; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; NOVA 21027; PHOSPHODIESTERASE INHIBITOR; PILOCARPINE; PLACEBO; PROSTAGLANDIN; RHO KINASE INHIBITOR; SNJ 1656; TAFLUPROST; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

CLINICAL TRIAL (TOPIC); CYTOSKELETON; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE THERAPY; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRABECULAR MESHWORK; TRABECULOTOMY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; OPHTHALMIC SOLUTIONS; PREDICTIVE VALUE OF TESTS; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 79958812858     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.579901     Document Type: Review

References (100)

1. Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93 (Pubitemid 26158268)
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20 (Pubitemid 38670330)
3. Konstas AG, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology 2006;113:761-5.e1
4. Lee AC, Mosaed S, Weinreb RN, et al. Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients. Ophthalmology 2007;114:666-70 (Pubitemid 46483689)
5. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
6. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edition. Editrice DOGMA S.r.l.; Savona, Italy: 2008
7. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85 (Pubitemid 40916921)
8. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73 (Pubitemid 30624384)
9. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53 (Pubitemid 33032760)
10. Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective?. J Glaucoma 2004;13:130-6 (Pubitemid 38372823)
11. Teping C, Wiedemann B. The COMOD system. A preservative-free multidose container for eyedrops. Klin Monbl Augenheilkd 1994;205:210-17 (Pubitemid 24339421)
12. Easty DL, Nemeth-Wasmer G, Vounatsos JP, et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006;90:574-8
13. Rouland JF, Morel-Mandrino P, Elena PP, et al. Timolol 0.1% gel (Nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 2002;216:449-54 (Pubitemid 36131995)
14. Uusitalo H, Pillunat LE, Ropo A; on behalf of the Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 2010;88:12-19
15. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-36
16. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010;27:837-45
17. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-671.e1
18. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
19. Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1757-64
20. Kaufman PL, Svedbergh B, Lutjen-Drecoll E. Medical trabeculocanalotomy in monkeys: with cytochalasin B or EDTA. Ann Ophthalmol 1979;11:795-7
21. Peterson JA, Tian B, Bershadsky AD, et al. Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci 1999;40:931-41 (Pubitemid 29153259)
22. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42:1029-37 (Pubitemid 32289800)
23. Waki M, Yoshida Y, Oka T, et al. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-4 (Pubitemid 34253206)
24. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor,SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;126:309-15 (Pubitemid 351398453)
25. A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP). Available from: http://clinicaltrials.gov/ct2/show/NCT00902200. Last accessed 14 January 2011
26. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, et al. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003;44:1117-25 (Pubitemid 36300758)
27. Pang IH, Fleenor DL, Hellberg PE, et al. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest Ophthalmol Vis Sci 2003;44:3502-10 (Pubitemid 36909788)
28. Lan YQ, Zhang C, Xiao JH, et al. Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. Mol Vis 2009;15:1977-87
29. Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005;46:3795-9 (Pubitemid 44264688)
30. Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther 2007;320:258-65 (Pubitemid 46025742)
31. Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study. Available from: http://www.medicalnewstoday.com/articles/192124.php. Last accessed 14 January 2011
32. A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01123785. Last accessed 14 January 2011
33. Siegner SW, Netland PA, Schroeder A, et al. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J Glaucoma 2000;9:334-9 (Pubitemid 32429205)
34. Campana G, Bucolo C, Murari G, et al. Ocular hypotensive action of topical flunarizine in the rabbit: role of s-1 recognition sites. J Pharmacol Exp Ther 2002;303:1086-94 (Pubitemid 35424393)
35. Wang RF, Gagliuso DJ, Podos SM. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys: J Glaucoma. 2008;17:73-8 (Pubitemid 351321482)
36. Abelson MB, Gilbert CM, Smith LM. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol 1988;105:155-9 (Pubitemid 18081310)
37. Abreu MM, Kim YY, Shin DH, et al. Topical verapamil and episcleral venous pressure. Ophthalmology 1998;105:2251-5 (Pubitemid 30191667)
38. Mansouri K, Silva SE, Shaarawy T. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. J Glaucoma 2010
39. Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease. Available athttp://clinicaltrials.gov/ct2/show/NCT01254370. Last accessed 14 January 2011
40. Ocular Hypotensive Efficacy of AR-102. Available from: http://clinicaltrials.gov/ct2/show/NCT00523250. Last accessed 14 January 2011
41. Borghi V, Bastia E, Guzzetta M, et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther 2010;26:125-32
42. Gabelt BT, Millar CJ, Kiland JA, et al. Effects of serotonergic compounds on aqueous humor dynamics in monkeys: Curr Eye Res. 2001;23:120-7 (Pubitemid 34499634)
43. Akaishi T, Takagi Y, Matsugi T, et al. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma 2004;13:312-18 (Pubitemid 38944200)
44. Kobayashi H, Kobayashi K, Okinami S. Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma 2004;13:73-80 (Pubitemid 38112358)
45. Yoshikawa K, Katsushima H, Kimura T, et al. Addition of or switch to topical bunazosin hydrochloride in elderly patients with normal-tension glaucoma: a one-year follow-up study. Jpn J Ophthalmol 2006;50:443-8 (Pubitemid 44496511)
46. Tolerance and Effect on Intraocular Pressure After Administration of SYL040012. Available from: http://clinicaltrials.gov/ct2/show/NCT00990743. Last accessed 14 January 2011
47. Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marijuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87:222-8 (Pubitemid 10130590)
48. McIntosh BT, Hudson B, Yegorova S, et al. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 2007;152:1111-20 (Pubitemid 350166054)
49. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc 2002;100:215-22; discussion 222-4
50. Tomida I, Azuara-Blanco A, House H, et al. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15:349-53 (Pubitemid 44434985)
51. Laine K, Jarvinen K, Mechoulam R, et al. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002;43:3216-22
52. Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010;19:75-6
53. Granero GE, Longhi MR. Promising complexes of acetazolamide for topical ocular administration. Expert Opin Drug Deliv 2010;7:943-53
54. Gudmundsdottir E, Stefansson E, Bjarnadottir G, et al. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:3552-4
55. Shah GB, Sharma S, Mehta AA, et al. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol 2000;36:169-75 (Pubitemid 30659836)
56. Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys: J Ocul Pharmacol. 1990;6:1-7 (Pubitemid 20238585)
57. Loftsson T, Thorisdottir S, Fridriksdottir H, et al. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol 2010;88:337-41
58. Al-Sereiti MR, Turner P. Effect of captopril (an angiotensin-converting enzyme inhibitor) on intraocular pressure in healthy human volunteers. J Ocul Pharmacol 1989;5:1-5 (Pubitemid 19111978)
59. Costagliola C, Di Benedetto R, De Caprio L, et al. Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur J Ophthalmol 1995;5:19-25
60. Chiselita D, Vancea PP, Haulica I. The ocular hypotonic effect induced by an angiotensin-converting enzyme inhibitor (captopril). Oftalmologia 1996;40:18-25
61. Wang RF, Podos SM, Mittag TW, et al. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res 2005;80:629-32 (Pubitemid 40602963)
62. Costagliola C, Verolino M, De Rosa ML, et al. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res 2000;71:167-71
63. Kaiser HJ, Graf T, Krejci G, et al. A new angiotensin-II-receptor blocker, CGP 48933: local tolerance and effect on intraocular pressure. A pilot study. Eur J Ophthalmol 1997;7:35-9 (Pubitemid 27140439)
64. Vaajanen A, Vapaatalo H, Kautiainen H, et al. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci 2008;49:2557-62
65. Zhang X, Clark AF, Yorio T. Interactions of endothelin-1 with dexamethasone in primary cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003;44:5301-8 (Pubitemid 37475402)
66. Thieme H, Stumpff F, Ottlecz A, et al. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2001;42:3193-201 (Pubitemid 33740679)
67. Thieme H, Schimmat C, Munzer G, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2006;47:938-45 (Pubitemid 46768325)
68. Konno T, Maruichi M, Takai S, et al. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol 2005;524:132-7 (Pubitemid 41606825)
69. Phillips CI, Green K, Gore SM, et al. Eye drops of RU 486-6, a peripheral steroid blocker, lower intraocular pressure in rabbits. Lancet 1984;1:767-8 (Pubitemid 14173152)
70. Zhang X, Krishnamoorthy RR, Prasanna G, et al. Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells. Exp Eye Res 2003;76:261-72 (Pubitemid 36263325)
71. Wiederholt M, Sturm A, Lepple WA. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 1994;35:2515-20 (Pubitemid 24137048)
72. Ito Y, Nagai N, Shimomura Y. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-beta-cyclodextrin in rabbit. Biol Pharm Bull 2010;33:1574-8
73. Borghi V, Bastia E, Guzzetta M, et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther 2010;26:125-32
74. Dortch-Carnes J, Russell KR. Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology 2006;77(7):17-24
75. Rasmussen CA, Gabelt BT, Kaufman PL. Aqueous humor dynamics in monkeys: in response to the kappa opioid agonist bremazocine. Trans Am Ophthalmol Soc 2007;105:225-38; discussion 238-9 (Pubitemid 352031778)
76. Lee KC, Silver PJ, Bode DC, et al. Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats. Methods Find Exp Clin Pharmacol 1993;15:527-34 (Pubitemid 24015832)
77. Hoyng PF, Groeneboer MC, Busch MJ. Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. Exp Eye Res 1991;52:511-17
78. Borras T, Gabelt BT, Klintworth GK, et al. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001;3:437-49 (Pubitemid 33684780)
79. Gabelt BT, Hu Y, Vittitow JL, et al. Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp Eye Res 2006;82:935-44
80. Hu Y, Gabelt BT, Kaufman PL. Monkey organ-cultured anterior segments; technique and response to H-7. Exp Eye Res 2006;82:1100-8
81. Liu X, Hu Y, Filla MS, et al. The effects of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis 2005;11:1112-21 (Pubitemid 41819512)
82. Gerometta R, Spiga MG, Borras T, et al. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci 2010;51:3042-8
83. Spiga MG, Borras T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest Ophthalmol Vis Sci 2010;51:3029-41
84. Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011
85. Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System. Available from: http://clinicaltrials.gov/ct2/show/NCT01080209. Last accessed 14 January 2011
86. Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy. Available from: http://clinicaltrials.gov/ct2/ show/NCT00693485. Last accessed 14 January 2011
87. Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Curr Opin Ophthalmol 2000;11(2):107-11 (Pubitemid 30164030)
88. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Arch Ophthalmol 1999;117:1540-4 (Pubitemid 29536483)
89. Koseki N, Araie M, Yamagami J, et al. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma 1999;8:117-23 (Pubitemid 32428005)
90. Koseki N, Araie M, Tomidokoro A, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 2008;115:2049-57
91. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010;2:CD006539
92. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
93. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16:114-21 (Pubitemid 43790804)
94. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8 (Pubitemid 37237370)
95. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6 (Pubitemid 26268834)
96. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009;147:725-735.e1
97. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-15
98. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30 (Pubitemid 29109440)
99. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995;113(2):216-21
100. Caprioli J, Coleman AL. Blood flow in glaucoma discussion. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010;149:704-12